TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02412722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sapanisertib
Description: Sapanisertib capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sapanisertib
Description: Sapanisertib capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sapanisertib
Description: Sapanisertib capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sapanisertib
Description: Sapanisertib capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sapanisertib
Description: Sapanisertib capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sapanisertib
Description: Sapanisertib capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel injection
Study: NCT04666597

Intervention type: PROCEDURE
Intervention: Modified CariesCare International management
Description: Interventions of this single-group study correspond to the 4D, to be implemented by the external DP, when possible with remote care and only with non-AGP:~1. D-DETERMINE risk assessing the protective and risk factors (social/medical/behavioural and clinical), using remote tools. Additionally, the description of tooth brushing behaviours and consumption of free sugars is included.~2. D-DETECT \& ASSESS: Caries staging and activity: ICDAS-merged visual criteria Caries OUT (without using compressed air, and avoiding radiographs). Clinical risk factors are assessed as well.~3. D-DECIDE a personalized care plan: individually designed for caries management home and clinical approaches.~4. D-DO: Appropriate Tooth-preserving \& Patient-level caries: Management plan at the Patient and at the Lesion level and the implementation of the Change Behaviour Tool (CBT) designed for this protocol.~The follow-up data will include a T1, T2 and T3 assessment.
Study: NCT04337229

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Artifical intelligent
Description: it is planned to create a technology that determines the comfort level of the newborn quickly and simply, easy to use, time-saving and can be used by the mobile device.
Study: NCT02773433

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proportional Assist Ventilation
Study: NCT01130103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine
Description: Paroxetine (controlled release) 12.5-50 milligrams (mg) daily for 22 weeks
Study: NCT01556867

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cord care by simple debridement (soaping, rinsing and drying)
Description: For children born during an experimental period of cord care will be done with a simple debridement (soaping and then rinsing and drying carefully)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cord care with the use of antiseptics
Description: For children born during a control period, cord care will be done with an antiseptic whose choice is left to the discretion of the healthcare team.~In this essay, it opted not to impose an antiseptic. Indeed, the objective of the trial is to compare the two strategies for management of care.
Study: NCT00876720

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS - Intervention 1
Description: Experimental repetitive transcranial magnetic stimulation (Alpine Biomed Mag Pro Option): 2000 stimuli of 20Hz rTMS over the left DLPFC (110% motor threshold) followed by 2000 stimuli of 1 Hz rTMS over the left temporal cortex DLPFC (110% motor threshold)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS - Intervention 2
Description: Experimental repetitive transcranial magnetic stimulation (Alpine Biomed Mag Pro Option): 2000 stimuli of 1 Hz rTMS over the left temporal cortex DLPFC (110% motor threshold)
Study: NCT03957694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romiplostim
Description: Romiplostim SC. Initial dose is 10 ug/kg/. Maximum dose is 20 ug/kg. Original duration is 6 months from first administration but if investigator decide that the patient is needed more treatment, they move to extention period and take treatment up to 1 year.
Study: NCT02129517

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IMPACT intervention
Description: Tailored, web-based educational short video clips

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Online education materials
Description: Online NCI-based educational materials

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: survey administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: survey administration
Description: Ancillary studies
Study: NCT01130103

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure Therapy
Description: Weekly for 10 weeks
Study: NCT01321905

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Supplementation with vitamin D2/D3
Description: Patients younger than 16 years of age are administered 35,000 IU ergo-/chole-calciferol per week divided into doses 5000 IU per day as a starting dose that is further adjusted by serum 25-hydroxy vitamin D concentration monitoring. The intervention time is 3 months, followed by 2-months wash-out period when patients do not take any more extra vitamin D but they are still monitored.~Patients 16 or more years of age are administered 50,000 IU ergo-/chole-calciferol per week divided into doses 7150 IU per day as a starting dose that is further adjusted by serum 25-hydroxy vitamin D concentration monitoring.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Supplementation with vitamin D2/D3
Description: Patients younger than 16 years of age are administered 35,000 IU ergo-/chole-calciferol per week divided into doses 5000 IU per day as a starting dose that is further adjusted by serum 25-hydroxy vitamin D concentration monitoring. The intervention time is 3 months, followed by 2-months wash-out period when patients do not take any more extra vitamin D but they are still monitored.~Patients 16 or more years of age are administered 50,000 IU ergo-/chole-calciferol per week divided into doses 7150 IU per day as a starting dose that is further adjusted by serum 25-hydroxy vitamin D concentration monitoring.
Study: NCT04951843

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Black soybean koji product
Description: Black soybean koji product
Study: NCT03116178

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group G -PVI( Masimo co oximeter) guided fluid therapy
Description: goal directed fluid therapy maintaining pvi 4-11. when pvi\<4 fluid rate is 50-60ml/hr and pvi\>11 200ml colloid bolus transfusion till pvi value achieves normal range.~In the control group crystalloid was administered @ 6-8 ml/kg and blood loss was replaced by colloids. Hourly urine output was measured and if less than 0.5ml/hr bolus crystalloid 100-200ml was administered

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group B- Body weight guided intravenous fluid @6-8ml/kg
Description: Intravenous fluid @6-8ml.kg and blood loss replacement with colloids maintaining urine output of 0.5ml/kg
Study: NCT00873886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir (Tamiflu)
Description: The following procedures will be performed on two occasions: once at least three days prior to the scheduled pregnancy termination procedure and again about eight weeks after the termination procedure.~A) Subject will take 75 mg of oseltamivir pill by mouth~B) Multiple blood draws (1 teaspoon each) over the next 48 hours after taking oseltamivir. Urine samples also will be collected.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood Draws
Description: Two blood draws (1 teaspoon each) will be performed: once during third trimester of pregnancy and again about eight weeks after delivery.
Study: NCT02407938

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rice meal
Study: NCT01588925

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cochlear Implantation
Description: Cochlear implantation using Hybrid L24 Implant

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cochlear Implantation
Description: Cochlear implantation using Hybrid L24 Implant

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cochlear Implantation
Description: Cochlear implantation using Hybrid L24 Implant

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cochlear Implantation+dexamethasone
Description: Cochlear implantation using Hybrid L24 Implant,dexamethasone (4mg/ml) in the round window

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cochlear Implantation+dexamethasone+hyaluronic acid
Description: Cochlear implantation using Hybrid L24 Implant,dexamethasone (4mg/ml) in the round window and hyaluronic acid (10mg/ml) in the electrode array
Study: NCT01566565

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Theophylline and Bambuterol
Description: Treatment 3: Theophylline, 300 mg plus Bambuterol, 20 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Theophylline and Bambuterol
Description: Treatment 3: Theophylline, 300 mg plus Bambuterol, 20 mg
Study: NCT01130103

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Prolonged Exposure Therapy
Description: Weekly for 10 weeks
Study: NCT02839928

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal ketamine
Description: The experimental arm consists of an single intranasal administration of Ketamine (Ketalar).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intranasal atomizer
Description: Ketamine will be applied to each nare via intranasal atomizer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EMLA
Study: NCT02361697

Intervention type: OTHER
Group type: OTHER
Intervention: DTI-MRI
Description: MRI of the brain with special DTI-sequences are performed in each child with multiple sclerosis or clinically isolated syndrome at timepoint of first manifestation and every 6 months in a longterm follow-up of 3 years
Study: NCT02399995

Intervention type: BEHAVIORAL
Intervention: HRQoL questionnaires.
Description: Questionnaires/Forms to be completed preoperatively in clinic with assistance from research study administrator:~* Baseline sociodemographic and clinical variable data sheet (RSA)~* EORTC QLQ-C30, QLQ-LMC21, EuroQoL EQ-5D-5L/VAS~* Baseline disease status and treatment assessment questionnaire Questionnaires/Forms to be completed at first postoperative clinic visit:~* EORTC QLQ-C30, QLQ-LMC21, EuroQoL EQ-5D-5L/VAS~Questionnaires/Forms to be mailed to patients at ± 2 month window at the following time points 6,12,18,24, and 36 months following hepatectomy:~* EORTC QLQ-C30, QLQ-LMC21, EuroQoL EQ-5D-5L/VAS~* Post surgical follow up disease status and treatment assessment questionnaire~* At 8 weeks following the mailing of the initial questionnaire package if no response has been received, research personnel will attempt to contact participants by phone.
Study: NCT01422382

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pitavastatin (NK-104)
Description: pitavastatin (NK-104) 4 mg once daily (QD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diltiazem (Cardizem LA) 240 mg QD
Description: Diltiazem (Cardizem LA) 240 mg QD
Study: NCT01514422

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: Minocycline 100 to 300mg per day for 8 weeks
Study: NCT04319731

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Amniotic Fluid
Description: Administration of amniotic fluid in SARS-CoV-2 positive patients
Study: NCT02857985

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D RA
Description: 3D RA is realised just after angioplasty.
Study: NCT00245154

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cediranib maleate
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: Given IV

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Given orally
Study: NCT02106546

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin administered intravenously over approximately 15 to 30 minutes at (AUC 6 mg/mL/min) immediately following paclitaxel infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin administered intravenously over approximately 15 to 30 minutes at (AUC 6 mg/mL/min) immediately following paclitaxel infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Description: Capsules taken orally twice a day, 12 hours apart.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel administered intravenously over 3 hours at a dose of 200 mg/m².

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel administered intravenously over 3 hours at a dose of 200 mg/m².

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to veliparib
Description: Capsules taken orally twice a day, 12 hours apart.
Study: NCT01271231

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Scaling and root planing plus placebo
Description: Single session of scaling and root planing using ultrasonic device. placebo tablets 500 mg, 1 tablet every 24 hours for 3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Scaling and root planing plus azythromycin
Description: Single session of scaling and root planing using ultrasonic device. Azythromycin tablets 500mg. 1 tablet every 24 hours for 3 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prophylaxis plus azythromycin
Description: Dental polishing using prophylaxis paste and rubber cups. Azythromycin tablets 500mg. 1 tablet every 24 hours for 3 days.
Study: NCT01373411

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ticagrelor
Description: ticagrelor 90 mg BID for 90 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 1 pill BID for 90 days
Study: NCT02002715

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inhaled budesonide
Description: inhaled Budesonide 2puff Q12h,total 400µg/day for 4 weeks inhaled Budesonide 2puff Q12h,total 400µg/day for 8 weeks inhaled Budesonide 2puff Q12h,total 400µg/day for 16 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inhaled budesonide
Description: inhaled Budesonide 2puff Q12h,total 400µg/day for 4 weeks inhaled Budesonide 2puff Q12h,total 400µg/day for 8 weeks inhaled Budesonide 2puff Q12h,total 400µg/day for 16 weeks
Study: NCT02857985

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: MRI is realised between 24h and 96h post angioplasty.
Study: NCT02002715

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inhaled budesonide
Description: inhaled Budesonide 2puff Q12h,total 400µg/day for 4 weeks inhaled Budesonide 2puff Q12h,total 400µg/day for 8 weeks inhaled Budesonide 2puff Q12h,total 400µg/day for 16 weeks
Study: NCT03074669

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT program
Description: ACT program consists of seven modules that have been adapted for the online environment. Each module is structured like a therapy session with at least two homework assignments.
Study: NCT03868280

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Antegrade femoral nailing Supine Position
Description: Antegrade femoral nailing in Supine Position using a Fracture Table

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Antegrade Femoral Nailing Lateral Position
Description: Antegrade femoral nailing in Lateral Position using a Free drape
Study: NCT02881216

Intervention type: DEVICE
Group type: OTHER
Intervention: Synergy Stent
Description: Patients with narrowed coronary artery disease qualifying for PCI were treated with Synergy stent implantation.

Intervention type: DEVICE
Group type: OTHER
Intervention: Currently common drug-eluting stent (DES)
Description: Patients with narrowed coronary artery disease qualifying for PCI were treated with DES implantation (Xience Prime, Resolute Integrity, Promus Element Plus)
Study: NCT01352455

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hemodialysis
Description: 5 days per week hemodialysis
Study: NCT00005626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan as outlined in treatment arm
Study: NCT00991978

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 89Zr-bevacizumab PET
Description: PET-scan with 89Zr-bevacizumab
Study: NCT04447222

Intervention type: OTHER
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Intervention: Survey Administration
Description: Complete survey
Study: NCT03673072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine (1000 mg/m2) in 250-500 ml 0.9% saline every three weeks on days 1 and 8 intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin (25 mg/m2) every three weeks on days 1 and 8 intravenously, in 1000 ml 0.9% saline with KCl 20 mmol and MgSO4 8 mmol during the one hour cisplatin infusion followed by 500 ml 0.9% saline over 30 minutes prior to gemcitabine; with adequate pre- and posthydration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oncologically radical margin-free (R0) resection
Description: Oncologically radical margin-free (R0) resection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Oncologically radical margin-free (R0) resection
Description: Oncologically radical margin-free (R0) resection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adjuvant chemotherapy
Description: Can be selected by Investigator's Choice
Study: NCT01681875

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: very low nicotine content cigarettes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: very low nicotine content cigarettes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: very low nicotine content cigarettes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: very low nicotine content cigarettes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: very low nicotine content cigarettes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: very low nicotine content cigarettes

Intervention type: OTHER
Group type: OTHER
Intervention: very low nicotine content cigarettes
Study: NCT06615999

Intervention type: PROCEDURE
Intervention: Simple fracture Tension band wiring
Description: OPS 5-793.27

Intervention type: PROCEDURE
Intervention: Simple fracture locked plate fixation
Description: OPS 5-793.k7
Study: NCT03377322

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic Capsule
Description: Probiotic - one capsule a day for four weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Capsule
Description: Placebo - one capsule a day for four weeks
Study: NCT00022854

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single-injection femoral nerve block
Description: Nerve block bolus with 30 mL levobupivacaine 0.25%, followed by continuous saline infusion

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Femoral nerve block 60-hour continuous injection
Description: Nerve block bolus with 30 mL levobupivacaine 0.25%, followed by continuous infusion (5 mL/hr for 50 hours) of 0.25% levobupivacaine

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Saline (control) injection into femoral nerve envelope
Description: Nerve block bolus with 30 mL saline, followed by continuous saline infusion
Study: NCT06615999

Intervention type: PROCEDURE
Intervention: Multi-fragmented tension band wiring
Description: OPS 5-794.17

Intervention type: PROCEDURE
Intervention: Multi-fragmented locked plate fixation
Description: OPS 5-794.k7
Study: NCT02735330

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: celiac plexus neurolysis using absolute alcohol
Description: celiac plexus blockade with 40 ml of diluted absolute alcohol(50%) 20 ml on either side of celiac axis in a 4 quadrant fashion

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo celiac plexus injection using saline
Description: Placebo celiac plexus injection with 40 ml of saline 20 ml on either side of celiac axis in a 4 quadrant fashion for blinding
Study: NCT04606472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SI-B003
Description: Administration by intravenous infusion.
Study: NCT04562792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: Eligible patients with relapsed and/or refractory acute leukemia will receive daunorubicin 6.75mg/m2 daily for 5 consecutive days.
Study: NCT02735330

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Frey's procedure
Description: Pancreatic head is partially resected (cored) along with longitudinal opening of duct along its entire length with limit of excavation of the head in the plane of the posterior wall of the Wirsung's duct and duct of Santorini is opened in the uncinate process. All the tissue above the plane, including the duct of Santorini is excised. The reconstruction is done with covering with a loop of jejunum in Roux-en-Y fashion which continues with the main pancreatic duct in the pancreatic body and tail.
Study: NCT03573089

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liberal phosphate target
Description: All phosphate-lowering medications in use at baseline will be discontinued. Phosphate-lowering medications will be prescribed only if serum phosphate concentration exceeds 2.50 mmol/L. The choice and dosages of phosphate-lowering medications will be at the discretion of treating physicians and/or participants.
Study: NCT02735330

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Frey's procedure
Description: Pancreatic head is partially resected (cored) along with longitudinal opening of duct along its entire length with limit of excavation of the head in the plane of the posterior wall of the Wirsung's duct and duct of Santorini is opened in the uncinate process. All the tissue above the plane, including the duct of Santorini is excised. The reconstruction is done with covering with a loop of jejunum in Roux-en-Y fashion which continues with the main pancreatic duct in the pancreatic body and tail.
Study: NCT03573089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intensive phosphate target
Description: This will be achieved by prescribing phosphate-lowering medications aimed to intensively lower serum phosphate concentration towards normal level (≤1.50 mmol/L). The choice and dosages of phosphate-lowering medications will be at the discretion of treating physicians and/or participants.